FDA fast-tracked dementia drug with known harms, reporter says
By
Kristen Fischer
Aug 18, 2023
An article in The BMJ is sounding the alarm that the US Food and Drug Administration fast-tracked approval for the dementia drug Rexulti (brexpiprazole) — even though trials show the drug is harmful.
Clinical briefs for Tuesday, August 1
By
Kristen Fischer
Aug 01, 2023
Vaccine for Alzheimer’s disease gets its start … Free online Parkinson’s course offers information for paid caregivers … Neurologists share tips for Alzheimer’s drugs … Eye experts offer safety...
Medicare costs could rise by $5B annually with expanded Alzheimer’s drug coverage: study
By
Alicia Lasek
May 12, 2023
Medicare costs could rise by $2 to $5 billion a year if CMS expands its coverage for newly approved Alzheimer’s disease drug Leqembi (lecanemab), investigators say.
NIA set to build $300M ‘real world’ Alzheimer’s database
By
Alicia Lasek
Apr 06, 2023
The goal is to collect real-world data on Alzheimer’s disease and create a centralized data hub, helping to expand and speed Alzheimer’s research.
Hurricanes hastened the deaths of adults with dementia, study finds
By
Alicia Lasek
Mar 08, 2023
People with Alzheimer’s and related dementias (ADRD) had higher mortality rates in U.S. counties that had recently experienced a hurricane disaster, investigators report.
Battle over Alzheimer’s drug coverage is hardly a no-brainer
By
John O'Connor
Feb 26, 2023
Well, it looks like we have a good old fashioned war of words developing over Alzheimer’s drug coverage. It’s a battle well worth watching.
Pay good providers more to care for dementia patients, researchers urge
By
Kimberly Marselas
Feb 09, 2023
Policymakers should consider incentivizing nursing homes to take patients with Alzheimer’s disease and related dementias, argue the authors of a new study that finds such patients currently are more...
Amyloid brain plaques not a sure sign of Alzheimer’s, researchers find
By
Alicia Lasek
Jan 12, 2023
A new study challenges the theory that an increase in brain amyloid protein signals Alzheimer’s disease. The findings may be especially relevant to clinicians as amyloid-targeting drugs such as Leqembi...
FDA approves new drug Leqembi to treat early Alzheimer’s disease
By
Alicia Lasek
Jan 09, 2023
The newly approved drug Leqembi (lecanemab) may slow progression of cognitive decline due to Alzheimer’s disease, trial data show. CMS says it may rethink Medicare coverage of drugs in Leqembi’s...
Vascular risk factors raise odds of Alzheimer’s disease in Blacks, Hispanics: study
By
Alicia Lasek
Jan 05, 2023
Vascular risk helps to explain the outsized odds of Alzheimer’s faced by African Americans and Hispanics in the United States, a new study has found.